https://pharmadog.xyz/news/173073 pharmadog en 2026-08-01T10:00:38.000Z Alnylam’s stock continues to fall as weekly roundup highlights Q2 earnings across biopharma https://pharmadog.xyz/news/171175 pharmadog en 2026-07-31T19:55:00.000Z Lidl US expands recall of Eridanous shortbread cookies over undeclared wheat, soy, milk, egg and coconut allergens https://pharmadog.xyz/news/169893 pharmadog en 2026-07-31T18:42:00.000Z Capricor CEO hints at possible lawsuit after FDA panel rejects Duchenne cardiomyopathy therapy https://pharmadog.xyz/news/169732 pharmadog en 2026-07-31T18:22:56.000Z AbbVie says Skyrizi maintains strong sales momentum as competition rises https://pharmadog.xyz/news/169573 pharmadog en 2026-07-31T17:22:21.000Z Pharma groups support revised 340B rebate pilot that permits limited rebate denials https://pharmadog.xyz/news/169489 pharmadog en 2026-07-31T17:02:27.000Z Trump administration revises 340B rebate pilot, sparking hospital backlash https://pharmadog.xyz/news/169337 pharmadog en 2026-07-31T16:36:25.000Z Moderna delays norovirus vaccine readout, cites insufficient infections https://pharmadog.xyz/news/169361 pharmadog en 2026-07-31T16:28:44.000Z Eli Lilly and Resilience commit $750 million to expand U.S. KwikPen device capacity for diabetes and obesity treatments https://pharmadog.xyz/news/169253 pharmadog en 2026-07-31T16:11:00.000Z Novo Nordisk's heart drug ziltivekimab fails Phase 3 trial, raising doubts on inflammation-targeted therapies https://pharmadog.xyz/news/169169 pharmadog en 2026-07-31T15:35:15.000Z Novo Nordisk's late-stage anti-inflammatory heart drug fails Phase 3 trial https://pharmadog.xyz/news/169213 pharmadog en 2026-07-31T15:29:20.000Z AbbVie shares slip 4% as Q2 immunology earnings beat falls short of lofty expectations https://pharmadog.xyz/news/169214 pharmadog en 2026-07-31T15:24:07.000Z Novo Nordisk’s IL-6 drug ziltivekimab misses Phase 3 cardiovascular endpoint, shares drop 9% https://pharmadog.xyz/news/169215 pharmadog en 2026-07-31T15:19:14.000Z Moderna sticks to 10% revenue growth goal despite Phase 3 norovirus vaccine miss https://pharmadog.xyz/news/169105 pharmadog en 2026-07-31T15:06:47.000Z Sanofi CEO pledges to rebuild trust and expand partnership with Regeneron https://pharmadog.xyz/news/168958 pharmadog en 2026-07-31T14:59:38.000Z Ratio Therapeutics secures $70M Series C for radiopharma trials as Vogenx eyes $67M IPO https://pharmadog.xyz/news/169002 pharmadog en 2026-07-31T14:47:59.000Z Bexorg names Bruce Car as new chief scientific officer https://pharmadog.xyz/news/168809 pharmadog en 2026-07-31T13:28:17.000Z FDA advisory panel backs experimental Replimune melanoma therapy after two prior rejections https://pharmadog.xyz/news/168641 pharmadog en 2026-07-31T12:56:02.000Z Alnylam cuts TTR franchise guidance, market cap loses $10.8B as shares tumble 28% https://pharmadog.xyz/news/168642 pharmadog en 2026-07-31T12:39:03.000Z UniQure prepares for FDA advisory committee on Huntington’s gene therapy amid rare-disease regulatory jitters https://pharmadog.xyz/news/168661 pharmadog en 2026-07-31T12:32:46.000Z Novo Nordisk's anti-inflammatory drug ziltivekimab fails to cut major heart events in Phase 3 trial https://pharmadog.xyz/news/168524 pharmadog en 2026-07-31T12:28:22.000Z Senate advances Erica Schwartz’s CDC director nomination to full Senate vote https://pharmadog.xyz/news/168193 pharmadog en 2026-07-31T11:00:06.000Z Ionis veteran scientist Frank Bennett to retire in 2027 as Recursion appoints its first AI chief https://pharmadog.xyz/news/168194 pharmadog en 2026-07-31T10:42:02.000Z Karyopharm stock tumbles after Phase 3 Xpovio trial fails in endometrial cancer https://pharmadog.xyz/news/168720 pharmadog en 2026-07-31T08:59:00.000Z Novo Nordisk's ziltivekimab fails phase 3 trial, jeopardizing CKD program https://pharmadog.xyz/news/167813 pharmadog en 2026-07-31T08:30:00.000Z ADA’s reputation erodes after controversial physician expulsions at annual meeting https://pharmadog.xyz/news/167814 pharmadog en 2026-07-31T08:30:00.000Z Opinion: Limb girdle muscular dystrophy patients face a maddening reality https://pharmadog.xyz/news/167815 pharmadog en 2026-07-31T08:30:00.000Z Authors rebut mischaracterization of their 2023 Lancet Covid study in recent op-ed https://pharmadog.xyz/news/167816 pharmadog en 2026-07-31T08:30:00.000Z Syphilis cases rise among unhoused drug users at San Diego-Tijuana border as researchers face NIH limits and penicillin shortage https://pharmadog.xyz/news/167444 pharmadog en 2026-07-31T07:24:14.000Z Latigo Biotherapeutics reports non-opioid drug cuts acute pain in Phase 2b trial https://pharmadog.xyz/news/167445 pharmadog en 2026-07-31T07:18:16.000Z Apnimed secures $192 million IPO to fund sleep-apnea drug program targeting 2027 launch https://pharmadog.xyz/news/167872 pharmadog en 2026-07-31T04:10:00.000Z Apnimed upsizes IPO to $192 million to fund launch of oral sleep‑apnea drug https://pharmadog.xyz/news/156560 pharmadog en 2026-07-31T04:00:00.000Z Abiomed recalls 14Fr Low Profile Introducer Kits over thrombus risk https://pharmadog.xyz/news/170189 pharmadog en 2026-07-31T04:00:00.000Z ResMed issues correction for Astral ventilators due to electrical component failure risk https://pharmadog.xyz/news/171748 pharmadog en 2026-07-31T00:00:00.000Z FDA releases draft guidance on container closure and device components for biosimilar combination products https://pharmadog.xyz/news/171747 pharmadog en 2026-07-31T00:00:00.000Z FDA announces reorganization and CTAGTAC votes on Duchenne muscular dystrophy and melanoma therapies https://pharmadog.xyz/news/165781 pharmadog en 2026-07-30T22:29:40.000Z FDA advisory panel backs Replimune’s melanoma immunotherapy combined with Opdivo https://pharmadog.xyz/news/165614 pharmadog en 2026-07-30T21:25:00.000Z FDA advisory panel backs Replimune's melanoma therapy RP1, raising approval prospects